Abstract
Pre-clinical studies indicate that changes in progesterone levels across menstrual cycle phases modulate the behavioral effects of sedative drugs acting at GABAA receptor sites. In this study, seven healthy women learned to discriminate triazolam (0.25 mg/70 kg) from placebo. After acquiring the discrimination, a range of triazolam doses (0.00, 0.06, 0.12 and 0.25 mg/70 kg) was tested during the early follicular and mid-luteal menstrual cycle phases. During the mid-luteal phase, when progesterone levels were elevated, 0.12 mg/70 kg triazolam was identified as the active triazolam training dose (0.25 mg/70 kg), whereas 0.12 mg/70 kg triazolam was identified as placebo during the early follicular phase, when progesterone levels were low. Triazolam engendered prototypical sedative effects on subjective effect, performance and cardiovascular measures that were generally independent of cycle phase. These results suggest that the discriminative stimulus effects of the positive GABAA modulator, triazolam, are sensitive to menstrual cycle phase in healthy adult women.
Original language | English |
---|---|
Pages (from-to) | 276-280 |
Number of pages | 5 |
Journal | Drug and Alcohol Dependence |
Volume | 94 |
Issue number | 1-3 |
DOIs | |
State | Published - Apr 1 2008 |
Bibliographical note
Funding Information:Funding : Funding for this study was provided by DA-09098 from the National Institute on Drug Abuse (NIDA, THK) and P20 RR 15592 from the National Center for Research Resources (NCRR, THK); Shanna Babalonis was supported by T32 DA-007304 (NIDA) during the preparation of this manuscript. NCRR and NIDA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
Keywords
- Drug discrimination
- Human
- Menstrual cycle
- Progesterone
- Triazolam
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)